There are 3397 resources available
384MO - Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)
Presenter: John Robertson
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Sarcoma
Resources:
Webcast
Discussion
Presenter: All Speakers
Session: Immunotherapy for head and neck cancer: What, when and how long?
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Melvin Lee Kiang Chua
Session: Immunotherapy for head and neck cancer: What, when and how long?
Resources:
Slides
Webcast
1324MO - CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis
Presenter: Ross Soo
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
655O - Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)
Presenter: Melissa Johnson
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1210MO - Comparison of clinical and radiological features-based and radiomics features-based models for pulmonary nodule malignancy prediction on CT images
Presenter: Fanrui Zeng
Session: Mini oral session - Basic science & translational research
Resources:
Abstract
Slides
Webcast
724O - EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER
Presenter: Eric Baudin
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA85 - Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
Presenter: Kim Nguyen Chi
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA90 - A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415)
Presenter: Viktor Gruenwald
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast